Skip to main content

Advertisement

Table 1 Characteristics of patients with small-bowel mucosal injuries per study group (polaprezinc treatment and no polaprezinc treatment, i.e., control)

From: Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study

Characteristic Polaprezinc (n = 10) Control (n = 10) Pvalue
Sex ratio (male/female) 9/1 7/3 N.S.*
Age (years); median (range) 78.5 (64-82) 75.5 (62-86) N.S.**
Hemoglobin concentration (g/dL); median (range) 13.6 (10.2-15.3) 13.7 (8-15) N.S.**
Indication for low-dose aspirin therapy    
 Valvular heart disease 3 2  
 Stroke 3 7 N.S.*
 Other 4 1  
Duration of low-dose aspirin (months); median (range) 64.5 (24-120) 48 (36-120) N.S.**
Anti-ulcer drug    
 H2 blocker 1 2 N.S.*
 PPI 3 1  
 None 6 7  
Initial CE findings    
 Median number of erosions/ulcers (range) 2 (0-6) 2 (0-10) N.S.**
 Median number of reddened lesions (range) 3 (0-7) 2 (0-7) N.S.**
CE score    
 Median score (range) 180 (0-450) 225 (0-225) N.S.**
 CE score by category    
  Normal or clinically insignificant change (<135) 3 4  
  Mild change (≥135 and <790) 7 6 N.S.*
  Moderate or severe change (≥790) 0 0  
  1. Number of patients are shown unless otherwise indicated.
  2. *by Fisher’s exact test **by Wilcoxon test.
  3. Abbreviations: CE, Capsule endoscopy; PPI, Proton pump inhibitor; N.S., Not significant.